Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

Idelalisib and Obinutuzumab Combination Shows Promise in Relapsed/Refractory Waldenström Macroglobulinemia

A combination regimen consisting of idelalisib and obinutuzumab led to promising response and survival rates in patients with relapsed and refractory Waldenström macroglobulinemia (WM),...

Reduced R-CHOP Intensity Does Not Compromise Survival in Older Patients With DLBCL

Research suggests higher dose intensity R-CHOP (rituximab, cyclophosphamide, doxorubicin hydro-chloride, vincristine sulfate, and prednisone) can improve survival in patients with diffuse large B-cell lymphoma...
On location

R-CHOP Versus R-EPOCH: No Difference in Survival for Patients With MYC-Rearranged, Double- or Triple-Hit...

Overall survival (OS) outcomes were similar between patients with MYC-rearranged diffuse large B-cell lymphoma (DLBCL) and double-hit lymphoma (DHL)/triple-hit lymphoma (THL) who were treated...

Orelabrutinib Receives Breakthrough Therapy Designation for Mantle Cell Lymphoma

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to the selective Bruton tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment...

What Is the Optimal Frontline Treatment for PTCL?

At the 2020 American Society of Hematology (ASH) Annual Meeting, researchers presented five-year results from the phase III ECHELON-2 trial, showing that patients with...
On location

ZUMA-5: Axicabtagene Ciloleucel Induces High Response Rates in Relapsed/Refractory Indolent NHL

According to research presented at EHA2021 Virtual, the annual congress of the European Hematology Association, treatment with the anti-CD19 chimeric antigen receptor (CAR) T-cell...
On location

B-Cell Depletion Linked to Prolonged COVID-19 in Lymphoma

A study of patients with B-cell non-Hodgkin lymphoma hospitalized for COVID-19 has found that these patients had a higher incidence of prolonged evolution of...
On location

Early Trial Shows Promising Results for Venetoclax Combination in Newly Diagnosed Mantle Cell Lymphoma

Adding venetoclax to rituximab and lenalidomide appeared to be safe and resulted in high rates of overall response and measurable residual disease (MRD) undetectability...
On location

PET-Adapted Therapy in Classical Hodgkin Lymphoma Allows Omission of Radiation Therapy

Patients with early-stage classical Hodgkin lymphoma (cHL) and bulky disease who achieved a response after two cycles of chemotherapy were able to avoid radiation...

Umbralisib Demonstrates Long-Term Safety and Clinical Activity in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL) have historically had poor long-term tolerance to phosphatidylinositol-3-kinase (PI3K) inhibitors. However, new study results published...